The US Bankruptcy Court granted an order for the extension of the exclusivity periods for Pear Therapeutics, Inc. on February 12, 2024. As per the order, the debtor?s exclusivity period to file its plan and to solicit votes on its plan, have been extended by 90 days i.e., up to May 6, 2024, and July 1, 2024, respectively.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -99.00% | -.--% | -.--% |
Mar. 22 | Disclosure Statement and Plan Approved on Interim Basis for Pear Therapeutics, Inc. | CI |
Mar. 04 | Combined Liquidation Plan and Disclosure Statement Filed by Pear Therapeutics, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 142 | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- PEARQ Stock
- News Pear Therapeutics, Inc.
- Third Motion for Exclusivity Period Extension Approved For Pear Therapeutics, Inc.